{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T12:48:50Z","timestamp":1744116530643,"version":"3.28.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The sublingual administration route as well as solid dispersion formation with macrogol 8000 and complexation with \u03b2-cyclodextrin (\u03b2-CyD) were investigated as ways for improving the absorption of perphenazine, a poorly water-soluble drug subjected to substantial first-pass metabolism.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The absorption of perphenazine was studied in rabbits after sublingual administration of perphenazine\/macrogol solid dispersion, solid perphenazine\/\u03b2-CyD complex and plain micronized perphenazine, as well as after peroral administration of an aqueous perphenazine solution. Solid formulations were prepared by freeze-drying (perphenazine\/macrogol solid dispersion) or spray-drying (perphenazine\/\u03b2-CyD complex).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key findings<\/jats:title>\n                  <jats:p>The value for area under the curve from 0 to 360 min (AUC0\u2013360 min) of perphenazine after peroral administration was only 8% of the AUC0\u2013360 min value obtained after intravenous administration, while the corresponding values for the sublingually administered formulations were 53% (perphenazine\/macrogol solid dispersion), 41% (perphenazine\/\u03b2-CyD complex) and 64% (micronized perphenazine). There are three possible mechanisms to explain these results: avoidance of the first-pass metabolism; good sublingual absorption of perphenazine; and rapid dissolution rate of perphenazine from the studied formulations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>With sublingual administration, the drug has to dissolve rapidly in a small volume of saliva. Based on the present absorption studies in rabbits, the solid dispersion preparation and cyclodextrin complexation were postulated to be useful ways to attain successful sublingual administration of perphenazine. Good sublingual absorption was also achieved by micronization of perphenazine. As far as we are aware, this paper is one of the first to evaluate the sublingual administration of a solid dispersion in vivo.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/j.2042-7158.2010.01173.x","type":"journal-article","created":{"date-parts":[[2010,11,16]],"date-time":"2010-11-16T12:51:29Z","timestamp":1289911889000},"page":"19-25","source":"Crossref","is-referenced-by-count":17,"title":["Fast-dissolving sublingual solid dispersion and cyclodextrin complex increase the absorption of perphenazine in rabbits"],"prefix":"10.1093","volume":"63","author":[{"given":"Elina","family":"Turunen","sequence":"first","affiliation":[{"name":"School of Pharmacy\/Pharmaceutical Chemistry, Faculty of Health Sciences, University of Eastern Finland , Kuopio,","place":["Finland"]},{"name":"Biocenter Kuopio, University of Eastern Finland , Kuopio,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janne","family":"Mannila","sequence":"additional","affiliation":[{"name":"School of Pharmacy\/Pharmaceutical Chemistry, Faculty of Health Sciences, University of Eastern Finland , Kuopio,","place":["Finland"]},{"name":"Biocenter Kuopio, University of Eastern Finland , Kuopio,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riikka","family":"Laitinen","sequence":"additional","affiliation":[{"name":"School of Pharmacy\/Pharmaceutics, Faculty of Health Sciences, University of Eastern Finland , Kuopio,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joakim","family":"Riikonen","sequence":"additional","affiliation":[{"name":"Laboratory of Industrial Physics, Department of Physics and Astronomy, University of Turku , Turku,","place":["Finland"]},{"name":"Department of Physics and Mathematics, Faculty of Science and Forestry, University of Eastern Finland , Kuopio,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vesa-Pekka","family":"Lehto","sequence":"additional","affiliation":[{"name":"Department of Physics and Mathematics, Faculty of Science and Forestry, University of Eastern Finland , Kuopio,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomi","family":"J\u00e4rvinen","sequence":"additional","affiliation":[{"name":"School of Pharmacy\/Pharmaceutical Chemistry, Faculty of Health Sciences, University of Eastern Finland , Kuopio,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarkko","family":"Ketolainen","sequence":"additional","affiliation":[{"name":"School of Pharmacy\/Pharmaceutics, Faculty of Health Sciences, University of Eastern Finland , Kuopio,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristiina","family":"J\u00e4rvinen","sequence":"additional","affiliation":[{"name":"School of Pharmacy\/Pharmaceutics, Faculty of Health Sciences, University of Eastern Finland , Kuopio,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pekka","family":"Jarho","sequence":"additional","affiliation":[{"name":"School of Pharmacy\/Pharmaceutical Chemistry, Faculty of Health Sciences, University of Eastern Finland , Kuopio,","place":["Finland"]},{"name":"Biocenter Kuopio, University of Eastern Finland , Kuopio,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2011,1,1]]},"reference":[{"key":"2024103013294075900_cit1","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v25.i5.20","article-title":"Sublingual drug delivery","volume":"25","author":"Goswami","year":"2008","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"2024103013294075900_cit2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jps.21793","article-title":"Non-invasive systemic drug delivery: developability considerations for alternate routes of administration","volume":"99","author":"Mathias","year":"2009","journal-title":"J Pharm Sci"},{"key":"2024103013294075900_cit3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v21.i3.20","article-title":"Mucosal drug delivery: membranes, methodologies, and applications","volume":"21","author":"Song","year":"2004","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"2024103013294075900_cit4","first-page":"CD003443","article-title":"Perphenazine for schizophrenia","volume":"1","author":"Hartung","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"2024103013294075900_cit5","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ejpb.2008.09.001","article-title":"Intraorally fast-dissolving particles of a poorly soluble drug: preparation and in vitro characterization","volume":"71","author":"Laitinen","year":"2009","journal-title":"Eur J Pharm Biopharm"},{"key":"2024103013294075900_cit6","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.addr.2007.05.012","article-title":"Cyclodextrins as pharmaceutical solubilizers","volume":"59","author":"Brewster","year":"2007","journal-title":"Adv Drug Deliv Rev"},{"key":"2024103013294075900_cit7","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1211\/jpp.60.9.0002","article-title":"Enhanced solubility and dissolution rate of lamotrigine by inclusion complexation and solid dispersion technique","volume":"60","author":"Shinde","year":"2008","journal-title":"J Pharm Pharmacol"},{"key":"2024103013294075900_cit8","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.ejps.2003.11.014","article-title":"Solid dispersions based on inulin for the stabilisation and formulation of \u03949-tetrahydrocannabinol","volume":"21","author":"van Drooge","year":"2004","journal-title":"Eur J Pharm Sci"},{"key":"2024103013294075900_cit9","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1211\/jpp.61.06.0006","article-title":"Cefuroxime axetil solid dispersion with polyglycolized glycerides for improved stability and bioavailability","volume":"61","author":"Dhumal","year":"2009","journal-title":"J Pharm Pharmacol"},{"key":"2024103013294075900_cit10","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.addr.2007.05.011","article-title":"Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates","volume":"59","author":"Blagden","year":"2007","journal-title":"Adv Drug Deliv Rev"},{"key":"2024103013294075900_cit11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1081\/PDT-120027417","article-title":"Micron-size drug particles: common and novel micronization techniques","volume":"9","author":"Rasenack","year":"2004","journal-title":"Pharm Dev Technol"},{"key":"2024103013294075900_cit12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ejpb.2007.05.010","article-title":"Dissolution enhancement of fenofibrate by micronization, cogrinding and spray-drying: comparison with commercial preparations","volume":"68","author":"Vogt","year":"2008","journal-title":"Eur J Pharm Biopharm"},{"key":"2024103013294075900_cit13","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0378-5173(96)04763-1","article-title":"Bioavailability of danazol-hydroxypropyl-\u03b2-cyclodextrin complex by different routes of administration","volume":"145","author":"Badawy","year":"1996","journal-title":"Int J Pharm"},{"key":"2024103013294075900_cit14","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/jps.10163","article-title":"Development and in vivo evaluation of buccal tablets prepared using danazol-sulfobutylether 7 \u03b2-cyclodextrin (SBE 7) complexes","volume":"91","author":"Jain","year":"2002","journal-title":"J Pharm Sci"},{"key":"2024103013294075900_cit15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejps.2005.04.020","article-title":"Effects of RM-\u03b2-CD on sublingual bioavailability of \u03949-tetrahydrocannabinol in rabbits","volume":"26","author":"Mannila","year":"2005","journal-title":"Eur J Pharm Sci"},{"key":"2024103013294075900_cit16","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1021\/js990163p","article-title":"Increased bioavailability of clomipramine after sublingual administration in rats","volume":"88","author":"Yoo","year":"1999","journal-title":"J Pharm Sci"},{"key":"2024103013294075900_cit17","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1211\/jpp.60.10.0003","article-title":"Formulation and evaluation of primaquine phosphate taste-masked rapidly disintegrating tablet","volume":"60","author":"Shah","year":"2008","journal-title":"J Pharm Pharmacol"},{"key":"2024103013294075900_cit18","doi-asserted-by":"crossref","first-page":"E55","DOI":"10.1208\/pt070255","article-title":"Formulation and optimization of mouth dissolve tablets containing rofecoxib solid dispersion","volume":"7","author":"Sammour","year":"2006","journal-title":"AAPS PharmSciTech"},{"key":"2024103013294075900_cit19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1034\/j.1600-0781.2001.017001011.x","article-title":"Pharmacokinetic behaviour of sublingually administered 8-methoxypsoralen for PUVA therapy","volume":"17","author":"Shephard","year":"2001","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"2024103013294075900_cit20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jchromb.2008.07.010","article-title":"Development and validation of a gas chromatographic-mass spectrometric method for quantitative determination of perphenazine in rabbit plasma after sublingual administration","volume":"872","author":"Turunen","year":"2008","journal-title":"J Chromatogr B"},{"key":"2024103013294075900_cit21","first-page":"117","article-title":"Phase-solubility techniques","volume-title":"Advances in Analytical Chemistry and Instrumentation","author":"Higuchi","year":"1965"},{"key":"2024103013294075900_cit22","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/jps.20766","article-title":"Precipitation complexation method produces cannabidiol\/\u03b2-cyclodextrin inclusion complex suitable for sublingual administration of cannabidiol","volume":"96","author":"Mannila","year":"2007","journal-title":"J Pharm Sci"},{"key":"2024103013294075900_cit23","first-page":"190","article-title":"The case of k independent samples","volume-title":"Nonparametric Statistics for the Behavioral Sciences","author":"Siegel","year":"1988","edition":"2nd"},{"key":"2024103013294075900_cit24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/jps.20312","article-title":"A rabbit model for sublingual drug delivery: comparison with human pharmacokinetic studies of propranolol, verapamil and captopril","volume":"95","author":"Dali","year":"2006","journal-title":"J Pharm Sci"},{"key":"2024103013294075900_cit25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF03190004","article-title":"Pharmacokinetics of midazolam: comparison of sublingual and intravenous routes in rabbit","volume":"24","author":"Odou","year":"1999","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2024103013294075900_cit26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(98)00052-0","article-title":"Mechanisms of drug release from cyclodextrin complexes","volume":"36","author":"Stella","year":"1999","journal-title":"Adv Drug Deliv Rev"},{"key":"2024103013294075900_cit27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0378-5173(94)00364-B","article-title":"The use of amorphous model substances to study mechanically activated materials in the solid state","volume":"119","author":"Elamin","year":"1995","journal-title":"Int J Pharm"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.2042-7158.2010.01173.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/63\/1\/19\/60235640\/j.2042-7158.2010.01173.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/63\/1\/19\/60235640\/j.2042-7158.2010.01173.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T18:58:00Z","timestamp":1730314680000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/63\/1\/19\/6135454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,1]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2011,1,1]]},"published-print":{"date-parts":[[2011,1,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.2042-7158.2010.01173.x","relation":{},"ISSN":["2042-7158","0022-3573"],"issn-type":[{"type":"electronic","value":"2042-7158"},{"type":"print","value":"0022-3573"}],"subject":[],"published-other":{"date-parts":[[2011,1]]},"published":{"date-parts":[[2011,1,1]]}}}